drugset / Trial / NCT06729320
A Randomized Controlled, Open, Single-center Clinical Study Evaluating the Efficacy and Safety of Umbilical Cord Blood Mononuclear Cells in Patients with Refractory Immune Effector Cell-related Hemocytopenia
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the safety and efficacy of umbilical cord blood mononuclear cell in the treatment of refractory immune effector cell-related hemocytopenia by observing the efficacy related factors and adverse reactions.
Timeline
- Start
- 2024-12-01
- Primary completion
- 2025-06-01
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Umbilical cord blood mononuclear cells | Cell therapy | 3e+08 cells | Intravenous |